LRMR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
34.4M
+10.4%
31.1M
-51.4%
64.0M
+29.3%
49.5M
+78.1%
27.8M
R&D
28.0M
+11.9%
25.0M
-57.8%
59.4M
+32.1%
44.9M
+92.3%
23.4M
SG&A
6.4M
+4.4%
6.1M
+31.0%
4.6M
+1.7%
4.6M
+3.3%
4.4M
Operating Income
-34351000
-10.4%
-31117000
+51.4%
-64018000
-29.3%
-49499000
-78.1%
-27792000
EBITDA
-34289000
-10.4%
-31053000
+51.4%
-63931000
-29.4%
-49411000
-78.3%
-27705000
Net Income
-32782000
-10.7%
-29613000
+52.6%
-62498000
-31.0%
-47712000
-82.2%
-26182000
EPS (Basic)
$-0.30
+3.2%
$-0.31
+57.5%
$-0.73
-19.7%
$-0.61
-48.8%
$-0.41
EPS (Diluted)
$-0.30
+3.2%
$-0.31
+57.5%
$-0.73
-19.7%
$-0.61
-48.8%
$-0.41
Shares (Diluted)
104.4M
+16.2%
89.8M
+5.1%
85.5M
+9.1%
78.3M
+22.3%
64.0M
Larimar Therapeutics (LRMR) โ€” Financials